Loading...
Market
What will be the next significant legal action involving BioNTech's COVID-19 vaccine royalties in 2025?
2
Resolution / Starting Odds
New lawsuit filed • 25%
Another settlement reached • 25%
Patent dispute resolution • 25%
No significant legal action • 25%
Court filings, press releases, or official announcements
Story
BioNTech Settles COVID-19 Vaccine Royalties, Paying $791.5M to NIH and $467M to UPenn
Dec 27, 2024, 02:00 PM
BioNTech has reached two separate settlement agreements concerning royalty payments related to its COVID-19 vaccine. The company will pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania. These agreements were confirmed by BioNTech in recent filings. The settlements address disputes over whether royalties were owed based on the locations where the licensed products were manufactured and sold. Despite these settlements, BioNTech will retain license rights under certain patents held by the University of Pennsylvania.
View original story
Similar markets
Upheld • 25%
Other • 25%
Settled • 25%
Overturned • 25%
AstraZeneca • 25%
Other • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Warning issued • 25%
No action taken • 25%
Investigation initiated • 25%
Recall issued • 25%
Contamination confirmed, no recall • 25%
No significant contamination found • 25%
Investigation inconclusive • 25%
Contamination confirmed, recall issued • 25%
Other • 25%
Acknowledge issues and propose changes • 25%
No official response • 25%
Deny allegations and defend actions • 25%
FDA • 25%
WHO • 25%
CDC • 25%
Pfizer • 25%
No • 50%
Yes • 50%
